https://www.selleckchem.com/products/AC-220.html
BACKGROUND Through enhancement of the Wnt signalling pathway, R-spondins are oncogenic drivers in colorectal cancer. Experimental data suggest that the R-spondin/Wnt axis stimulates vascular endothelial growth factor (VEGF)-dependent angiogenesis. We therefore hypothesise that variations within R-spondin genes predict outcome in patients with metastatic colorectal cancer (mCRC) treated with upfront FOLFIRI and bevacizumab. PATIENTS AND METHODS 773 patients with mCRC enrolled in the randomised phase III FIRE-3 and TRIBE trials and receivi
Like
Comment
Share
